influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes
split virion, inactivated - influenza virus split virion - suspension for injection
supemtek
sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - influenza, human - vaccines - supemtek is indicated for active immunization for the prevention of influenza disease in adults.supemtek should be used in accordance with official recommendations.
fluenz tetra
astrazeneca ab - a/darwin/9/2021 (h3n2) - like strain (a/norway/16606/2021, medi 355293) / a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/1/2020, medi 340505) / b/austria/1359417/2021 - like strain (b/austria/1359417/2021, medi 355292) / b/phuket/3073/2013 - like strain (b/phuket/3073/2013, medi 306444) - influenza, human - influenza vaccines, influenza, live attenuated - prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. the use of fluenz tetra should be based on official recommendations.
aflunov(r) prepandemic influenza vaccine, h5n1 (surface antigen, inactivated, adjuvanted) 0.5ml pre-filled syringe
seqirus pty ltd - influenza virus haemagglutinin -
pandemic influenza vaccine h5n1 baxter (whole virion, vero cell derived, inactivated) suspension for injection 0.5 ml dose
au pharma pty ltd - influenza virus haemagglutinin, quantity: 15 microgram/ml - injection, suspension - excipient ingredients: trometamol; water for injections; sodium chloride; polysorbate 80 - pandemic influenza vaccine h5n1 baxter is indicated for prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official recommendations.
pandemic influenza vaccine h5n1 baxter
pharmacy retailing (nz) ltd t/a healthcare logistics - influenza vaccine whole virion, vero cell derived, inactivated 7.5ug (a(h5n1) (a/vietnam/1203/2004)); - suspension for injection - 7.5 mcg/0.5ml - active: influenza vaccine whole virion, vero cell derived, inactivated 7.5ug (a(h5n1) (a/vietnam/1203/2004)) excipient: polysorbate 80 sodium chloride trometamol water for injection - prophylaxis of influenza in an officially declared pandemic situation. the vaccine may only be marketed or distributed in accordance with the directives contained in the current version of the new zealand influenza pandemic action plan.
panvax h1n1 vaccine
seqirus (nz) ltd - influenza virus a/california/7/2009 (h1n1) - like strain 15ug - suspension for injection - 15 mcg/0.5ml - active: influenza virus a/california/7/2009 (h1n1) - like strain 15ug excipient: calcium chloride dihydrate dibasic sodium phosphate monobasic potassium phosphate monobasic sodium phosphate dihydrate potassium chloride sodium chloride thiomersal water for injection - for active immunisation to prevent influenza disease caused by the influenza a(h1n1) virus, in adults, adolescents and children 10 years of age and older.
vaxigrip vaccine
sanofi-aventis new zealand limited - influenza virus a/wellington/i/2004(h3n2)-like strain 10ug ([influenza virus a/wellington/i/2004 ivr-139(10 µg/ha)]); ; influenza virus b/shanghai/361/2002-like strain 15ug ([b/jiangsu/10/2003 (15µg/ha)]); ; influenza virus haemagglutinin type a/new caledonia/20/99 h1n1-like strain 15ug ([a/new caledonia/20/99 ivr-116 (15µg/ha)]); - solution for injection - 10µg/15µg/15µg per dose - active: influenza virus a/wellington/i/2004(h3n2)-like strain 10ug ([influenza virus a/wellington/i/2004 ivr-139(10 µg/ha)]) influenza virus b/shanghai/361/2002-like strain 15ug ([b/jiangsu/10/2003 (15µg/ha)]) influenza virus haemagglutinin type a/new caledonia/20/99 h1n1-like strain 15ug ([a/new caledonia/20/99 ivr-116 (15µg/ha)]) excipient: dibasic sodium phosphate dihydrate monobasic potassium phosphate neomycin sodium chloride water for injection
influvac
abbott medical laboratories ltd, israel - a/cambodia/e0826360/2020 (h3n2)-like strain; a/victoria/2570/2019 (h1n1)pdm09-like strain; b/washington/02/2019 (b/victoria lineage)-like virus - suspension for injection - b/washington/02/2019 (b/victoria lineage)-like virus 15 mcg/dose / 0.5 ml; a/cambodia/e0826360/2020 (h3n2)-like strain 15 mcg / 0.5 ml; a/victoria/2570/2019 (h1n1)pdm09-like strain 15 mcg / 0.5 ml - influenza, inactivated, split virus or surface antigen - influenza, inactivated, whole virus - influenza virus vaccine.
agrippal s1 influenza vaccine
seqirus pte. ltd. - influenza virus (sh) a/california/07/2009 (h1n1) pdm09- like strain; influenza virus (sh) a/hong kong/4801/2014 (h3n2) - like strain; influenza virus (sh) b/brisbane/60/2008 - like strain - injection - 15 mcg ha/0.5ml - influenza virus (sh) a/california/07/2009 (h1n1) pdm09- like strain 15 mcg ha/0.5ml; influenza virus (sh) a/hong kong/4801/2014 (h3n2) - like strain 15 mcg ha/0.5ml; influenza virus (sh) b/brisbane/60/2008 - like strain 15 mcg ha/0.5ml